Aging & Longevity, Metabolic Health, NAD+, NMN, Research

NMN lowers Cholesterol, bodyweight, and blood pressure in 28 day trial with overweight older adults

Nicotinamide Adenine Dinucleotide Augmentationin Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study

Overweight or obese (body mass index 25-42.5 kg/m2), middle-aged and older men and postmenopausal women, 45 years or older.

Participants were asked to take 2 MIB-626 tablets each containing 500 mg of βNMN for 28 days

The randomized participants were asked to take 2 tablets of the study medication orally twice daily for 28 consecutive days. They were asked not to make changes in their dietary intake or to start a weight-reducing diet and were instructed to maintain their usual physical activity during the course of the trial.

This study was just published Feb 6. It is sponsored by Metrobiotech, a company co-founded by Dr. Sinclair, and used their patented form of NMN called MIB 626.
MIB-626 is a special crystalline form of NMN created to be more stable than the standard NMN that was used back in 2016, but has little or no advantage over NMN now available on the market.
30 overweight adults (over 45 years old) were given either 1,000 mg NMN or placebo twice daily for 28 days. Significant improvements were:
  • Lower LDL Cholesterol
  • Lower Total Cholesterol
  • Lower Diastolic Blood Pressure
  • Lower Weight
  • Over 200% increase in NAD+ levels
There was a trend towards lower Systolic Blood Pressure and increased strength, but did not reach statistical significance.
Certainly not as striking as Dr. Sinclair’s research in mice, but not bad considering the short time frame and limited number of participants which make it harder to reach statistically significant findings.
It is yet another positive result for NMN in human studies.

Some quotes from the study below:

A regimen of 1000 mg of MIB-626 twice daily was safe and efficacious

MIB-626 treatment was associated with a substantial increase in blood NAD level from baseline to days 14 and 28

Circulating NMN levels did not change significantly in either group, except transiently 2 hours after the dose on day 28

Body weight decreased in the participants randomized to the MIB-626 group and increased in those assigned to the placebo group; between-group difference in change in body weight was statistically significant

Serum

A regimen of 1000 mg of MIB-626 twice daily was safe and efficacious

MIB-626 treatment was associated with a substantial increase in blood NAD level from baseline to days 14 and 28

Circulating NMN levels did not change significantly in either group, except transiently 2 hours after the dose on day 28

total cholesterol, low-density lipoprotein (LDL) cholesterol, and non-high–density lipoprotein (HDL) cholesterol levels decreased from baseline in the MIB-626 group

Diastolic blood pressure decreased from baseline in the MIB-626 group

Conclusions: MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure.